Activity Overview
This educational activity is an archive of the live presentation held on May 20, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward a global audience of oncology clinicians, including medical oncologists, thoracic oncologists, pulmonologists, advanced practice providers, oncology nurses, pharmacists, and other members of the multidisciplinary cancer care team involved in the management of patients with non–small cell lung cancer (NSCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess recent clinical trial and emerging pipeline data for TROP2-targeted ADCs and combination strategies in NSCLC
- Select evidence-informed treatment and sequencing strategies for patients with NSCLC across relevant biomarker subsets
- Evaluate appropriate interpretation of exploratory CNS activity signals for TROP2-targeted ADCs
Solange Peters, MD, PhD
Full Professor
Chair of Medical Oncology and Oncology Program
University Hospital of Lausanne
Lausanne, Switzerland
Benjamin P. Levy, MD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Sibley Memorial Hospital
Washington, DC
Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO
Associate Dean (Translation and Entrepreneurship)
Chairman, Department of Clinical Oncology
Li Shu Fan Professor of Clinical Oncology
Chinese University of Hong Kong
Sha Tin, Hong Kong
Maurice Pérol, MD
Lead
Thoracic Oncology Program
Medical Oncologist
Léon Bérard Cancer Centre
Lyon, France
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
PER is proud to partner with the European Thoracic Oncology Platform (ETOP).
